These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8740642)

  • 1. Immunoglobulin Inhibiting Reagent: evaluation of a new method for eliminating spurious elevations in CA125 caused by HAMA.
    Nicholson S; Fox M; Epenetos A; Rustin G
    Int J Biol Markers; 1996; 11(1):46-9. PubMed ID: 8740642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of ELISAs for quantification of HMFG1-specific human anti-mouse IgG and IgM antibodies.
    Oei AL; Boerman OC; Geurts-Moespot A; van Eerd JE; van Tienoven D; Courtenay-Luck N; Thomas CM; Massuger LF; Sweep FC
    Int J Biol Markers; 2007; 22(3):167-71. PubMed ID: 17922458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of IgG and IgM human anti-mouse antibodies (HAMA) interference in CA 125 measurements using affinity chromatography.
    Koper NP; Thomas CM; Massuger LF; Segers MF; Olthaar AJ; Verbeek AL
    Clin Chem Lab Med; 1998 Jan; 36(1):23-8. PubMed ID: 9594082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-murine antibody response to mouse monoclonal antibodies in cancer patients.
    Sakahara H; Saga T; Onodera H; Yao Z; Nakamoto Y; Zhang M; Sato N; Nakada H; Yamashina I; Endo K; Konishi J
    Jpn J Cancer Res; 1997 Sep; 88(9):895-9. PubMed ID: 9369938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different efficacy of various blocking reagents to eliminate interferences by human antimouse antibodies with a two-site immunoassay.
    Reinsberg J
    Clin Biochem; 1996 Apr; 29(2):145-8. PubMed ID: 8601323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody.
    Oei AL; Sweep FC; Massuger LF; Olthaar AJ; Thomas CM
    Gynecol Oncol; 2008 May; 109(2):199-202. PubMed ID: 18304620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human anti-mouse IgM and IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-muHMFG1.
    Oei AL; Sweep FC; Geurts-Moespot A; van Tienoven D; Von Mensdorff-Pouilly S; Thomas CM; Massuger LF
    Anticancer Res; 2008; 28(5A):2721-5. PubMed ID: 19035301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human antibody response to the intravenous and intraperitoneal administration of the F(ab')2 fragment of the OC125 murine monoclonal antibody.
    Maher VE; Drukman SJ; Kinders RJ; Hunter RE; Jennings J; Brigham C; Stevens S; Griffin TW
    J Immunother (1991); 1992 Jan; 11(1):56-66. PubMed ID: 1734949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chicken antibodies: a tool to avoid interference by human anti-mouse antibodies in ELISA after in vivo treatment with murine monoclonal antibodies.
    Larsson A; Mellstedt H
    Hybridoma; 1992 Feb; 11(1):33-9. PubMed ID: 1737638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to overcome the disturbing effects of human anti-mouse antibodies (HAMA) on in vitro assays.
    Oltrogge JB; Baum RP; Lema KN; Donnerstag B; Hör G
    Int J Biol Markers; 1997; 12(1):15-7. PubMed ID: 9176712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-specific immunoglobulin interactions may lead to false-positive results in assays for human anti-mouse monoclonal antibodies (HAMA).
    Papoian R
    J Immunoassay; 1992; 13(2):289-96. PubMed ID: 1430244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients.
    Tibben JG; Thomas CM; Massuger LF; Segers MF; Schijf CP; Corstens FH; Boerman OC
    Nucl Med Commun; 1995 Oct; 16(10):853-9. PubMed ID: 8570116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis.
    Nicholson S; Gooden CS; Hird V; Maraveyas A; Mason P; Lambert HE; Meares CF; Epenetos AA
    Oncol Rep; 1998; 5(1):223-6. PubMed ID: 9458326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma.
    Baum RP; Niesen A; Hertel A; Nancy A; Hess H; Donnerstag B; Sykes TR; Sykes CJ; Suresh MR; Noujaim AA
    Cancer; 1994 Feb; 73(3 Suppl):1121-5. PubMed ID: 8306256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMMULITE OM-MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors.
    Gebauer G; Rieger M; Jäger W; Lang N
    Anticancer Res; 1999; 19(4A):2535-6. PubMed ID: 10470190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bead-based ELISA for validation of ovarian cancer early detection markers.
    Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
    Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
    Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.
    Miotti S; Negri DR; Valota O; Calabrese M; Bolhuis RL; Gratama JW; Colnaghi MI; Canevari S
    Int J Cancer; 1999 Feb; 84(1):62-8. PubMed ID: 9988234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for artifacts in monitoring for the detection of tumor associated antigens (TAG-72 and CEA) in serum from patients undergoing MAb-based diagnostic and therapeutic protocols.
    Ferroni P; Milenic DE; Roselli M; Carrasquillo JA; Raubitschek A; Schlom J; Colcher D
    Int J Biol Markers; 1990; 5(4):166-76. PubMed ID: 2093732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.